Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Caffeine on Regadenoson SPECT MPI
NCT00826280Phase 3Completed
- Sponsor
- Astellas Pharma
- Start
- Mar 2009
- Primary completion
- Jul 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of regadenoson in coronary artery disease (CAD), sponsored by Astellas Pharma. Started Mar 2009; status: completed.
02
Drugs
regadenoson
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT00826280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00826280.